Tissue and plasma proteomics for early stage cancer detection,Molecular Omics

当前位置： X-MOL 学术 › Mol. Omics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tissue and plasma proteomics for early stage cancer detection
Molecular Omics ( IF 3.0 ) Pub Date : 2018-09-13 , DOI: 10.1039/c8mo00126j
Liyuan Peng _{1,

2,

3} , David I. Cantor _{4,

5,

6} , Canhua Huang _{1,

2,

3} , Kui Wang _{1,

2,

3} , Mark S. Baker _{6,

7} , Edouard C. Nice _{6,

8,

9}

Affiliation

The pursuit of novel and effective biomarkers is essential in the struggle against cancer, which is a leading cause of mortality worldwide. Biomarkers can be used as specific diagnostic tools, prognostic predictors, markers of the development of therapeutic resistance or even as therapeutic targets themselves. Through the application of sensitive and specific proteomic techniques, oncoproteomics investigates the proteins associated with cancer processes, to better understand their biological function/s and their associated pathways during tumorigenesis. Such studies seek to identify both potential biomarkers and drug targets in order to improve patient survival and quality of life whilst reducing the global health budget. Tissue and plasma are the most commonly utilised biological samples for such studies as they are readily available, non-invasive and generally acceptable. Here, we outline the relative advantages and disadvantages of the most frequently used techniques for cancer diagnosis, prognosis, treatment and surveillance, concentrating on the latest advances and application of tissue and plasma proteomics for novel cancer biomarker discovery and disease surveillance.

中文翻译：

用于早期癌症检测的组织和血浆蛋白质组学

在抗击癌症的斗争中，追求新颖有效的生物标记物至关重要，而癌症是全球范围内导致死亡的主要原因。生物标志物可以用作特定的诊断工具，预后指标，治疗抗性发展的标志物，甚至可以用作治疗靶标本身。通过应用敏感和特定的蛋白质组学技术，人体基因组学研究了与癌症过程相关的蛋白质，以更好地了解其在肿瘤发生过程中的生物学功能和相关途径。此类研究旨在识别潜在的生物标志物和药物靶标，以改善患者的生存率和生活质量，同时减少全球卫生预算。组织和血浆是此类研究中最常用的生物样品，因为它们很容易获得，无创且通常可以接受。在这里，我们概述了最常用的癌症诊断，预后，治疗和监测技术的相对优缺点，重点介绍了组织和血浆蛋白质组学在新型癌症生物标志物发现和疾病监测中的最新进展和应用。

更新日期：2018-12-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11